PPT-SOF/VEL + RBV

N 69 gt 18 years Failure to SOFVEL or SOFVEL VOX LEPTON study Any genotype Compensated cirrhosis allowed No HBV or HIV coinfection Openlabel SOFVEL 400100 mg FDC QD RBV weight based in twice daily dose . Out With the Old, In With the New. Current Standard of Care. NEUTRINO and FISSION. . SOF + RBV ± pegIFN for Treatment-naive Patients. NEUTRINO and FISSION. . SOF + RBV ± pegIFN for Treatment-naive Patients. Placebo. LDV/SOF + placebo. Randomisation*. 1 : 1. Double-blind. SIRIUS . Study. : LDV/SOF ± RBV for genotype 1 and cirrhosis with non response to prior PI therapy. Design. W24. W12. ≥ 18 years. Chronic HCV infection. 400/100 mg . qd. N = 120. N = 120. W12. SOF + RBV. > . 18 years. Chronic HCV infection. Genotype . 2. Naïve . or pre-treatment. with IFN-based regimen. Compensated cirrhosis allowed**. No HBV or HIV co-infection. With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: . Interim Results of a European Multicenter Compassionate Use Program. Herzer K,. 1. . Welzel. . HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAILAND. When to Treat HCV. . HCV Direct-Acting . Antivirals. (. DAAs. ) in . development. . OVERVIEW. Know your epidemic: what matters. 400/100/100 mg QD. N = 501. N = 440. W8. SOF/VEL 400/100 mg QD. >. 18 years. Chronic HCV infection. Genotype 1, 2, 3, 4, 5 or 6. Treatment-naïve or . IFN-experienced. Compensated cirrhosis **. allowed . in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. Open-label. Chronic HCV infection. Genotype 1 . Failure to achieve SVR. 12. . on a short-course of 1. st. line. LDV/SOF-containing regimen . No cirrhosis. N = 34. SVR. 12. Co-formulated ledipasvir-sofosbuvir (LDV 90 mg/SOF 400 mg) : 1 pill qd. in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. Interim Analysis of a French Multicenter Compassionate Use Program. Christophe Hézode,. 1. Victor De Ledinghen,. 2. Helene Fontaine,. 3. Fabien Zoulim,. 4. Pascal Lebray,. 5. Nathalie Boyer,. 6. IAPAC African Regional Capacity-Building Hub. Based in Johannesburg, South Africa. Mission: Strengthen clinician capacity to deliver HIV, HBV, and HCV treatment . Partners include:. . Supported through an educational grant from: . April 10. –14. , 2019. Vienna, Austria. Disclaimer. These non-promotional slides are intended to be used as educational material only in response to an unsolicited question or request. The double-dagger (. . Plus . Sofosbuvir. With or Without Ribavirin . for the Treatment of Chronic HCV . Genotype . 3 Infection: . Interim Results of a Multicenter . European Compassionate . Use . Program. Welzel. TM,. >. 18 years. Genotype 2, 3, 4, 5 or 6. HCV RNA . >. 10 000 IU/mL. Treatment-naive or treatment-experienced (with or without DAA). Compensated cirrhosis allowed. Creatinine clearance . >. 60 mL/min.